Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference:
Jefferies Cell and Genetic Medicine Summit
A live webcast, if recorded, of the presentation can be accessed under “News & Events” in the Investors section of the Company’s website at www.instilbio.com. The archived webcast will be available on the Company’s website shortly after the event.
About Instil Bio